ASNDAscendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies for rare endocrine diseases and other serious conditions with limited treatment options. Its current portfolio includes SKYTROFA for pediatric growth hormone deficiency and YORVIPATH for adults with chronic hypoparathyroidism, both built around the company’s TransCon technology platform. The company also advances a pipeline of product candidates in endocrinology and oncology, reflecting a focus on specialized, science-driven medicines. Headquartered in Hellerup, Denmark, Ascendis Pharma A/S operates across major markets in Europe, the United States, and other international regions through a global development and commercial organization. Its role in the financial market is tied to its position as a research-intensive healthcare company addressing niche therapeutic areas where innovation and regulatory execution are central to value creation.